Finnish biotech Nanoform has taken home the Excellence in Pharma Award for Formulation at this year's CPhI Pharma Awards. Receiving this highly contested prize is an acknowledgement of Nanoform’s commitment to innovation in the industry through its best-in-class Controlled Expansion of Supercritical Solutions nanonisation technology.
Nanoform has been awarded for its work helping international partners find innovative solutions for drug development and delivery. Its multi-patented nanonisation process has the ability to double the number of drug compounds reaching clinical trials by substantially improving dissolution rates and bioavailability.
CESS technology
The company's multi-patented and scalable CESS technology produces nanonised “designed-for-purpose” API particles, as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Nanoform's unique nanonisation technology provides novel opportunities in diverse value-enhancing drug delivery applications.
The technology also provides significant added value to the ocular, pulmonary, transdermal, and blood-brain barrier drug delivery space.
The CPhI Pharma Awards provide recognition to teams in the pharmaceutical industry that turn inspiration into innovation. Nominees in this year’s Formulation category included Cambrex, Lonza Capsugel and Glatt Pharmaceutical Services.
Edward Hæggström, CEO of Nanoform, commented: “We are delighted to have received this prestigious award. It is a fantastic testament to the hard work of the Nanoform team and their ability to deliver high-quality nanonisation services that help pharma companies develop life-changing medicines.”
